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varied from 19 for warts, to 27 for CIN 3 and approximately
450 for cancer and was similar for the differently aged cohorts.
Results were sensitive to the duration of vaccine efﬁcacy and cov-
erage. If vaccine coverage was as low as 30%, the NNV for
warts, CIN 3 and cancer would increase to 50, 57 and 1115
respectively. If the duration of efﬁcacy was only 10 years instead
of a lifetime, the NNV would increase to 62 for warts, 67 for
CIN 3 and over 1100 for cancer. CONCLUSION: These analy-
ses suggest that the NNV for warts and cervical pre-cancer using
a quadrivalent HPV vaccine is low, but will depend on the dura-
tion of vaccine efﬁcacy as well as coverage.
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OBJECTIVES: The Functional Assessment of Cancer Therapy—
Kidney Symptom Index (FKSI) is a 15-item scale that was devel-
oped and validated to assess symptoms and concerns of
advanced kidney cancer patients. The aim of this study was to
evaluate the factor structure of FKSI for possibly useful sub-
scales and assess the reliability of the sub-scales. METHODS:
Data for this study were obtained from a phase III clinical trial
of 903 advanced renal cancer patients. Patients were adminis-
tered FKSI questionnaire at baseline. Baseline data were analyzed
using exploratory factor analysis with oblique rotation (promax)
to evaluate the dimensional structure of FKSI. The internal con-
sistency of the subscales and overall scale was assessed using
Cronbach’s alpha. RESULTS: Four factors were identiﬁed con-
sisting of 13 of the 15 items of FKSI. The ﬁrst factor had two
items related to pain symptoms; the second factor had two items
related to respiratory symptoms; the third factor had ﬁve items
related to general symptoms of the disease and; the fourth factor
had four items related to quality of life. All four factors had good
reliability (alphas > 0.70). The internal consistency of the overall
13-item scale was excellent (alpha = 0.83). CONCLUSION: A
four-factor solution consisting of 13 items could easily be labeled
with clinically-meaningful concepts, indicating the possibility of
four underlying dimensions of kidney cancer symptomatology:
pain, respiratory, general symptoms and quality of life. Findings
supported the internal consistency of four sub-scales and overall
13-item scale. Sub-scale scores and the total index are reliable
and valid measure that can be used to determine the effect of
drug therapies on speciﬁc symptoms and concerns of advanced
kidney cancer.
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OBJECTIVES: To assess Australian men’s preferences for health
states (HS) speciﬁc to advanced stage prostate cancer (APC)
including baseline diagnoses of APC, response, no response,
disease progression and especially treatment-related toxicities by
severity apart from other components of the HS which is
methodologically different. METHODS: FACT-P QOL data
from patients with APC were used to compose HS narratives
consisting of physical, social, emotional, functional well-being,
additional concerns domains. Treatment-related mild, moderate,
severe and life-threatening toxicities were described separately.
100 Australian men were recruited and interviewed using stan-
dard gamble techniques (SG). Baseline diagnoses of APC,
response, no response and disease progression using SG as usual
with oscillating risks of perfect health (1) and immediate death
(0) as anchors OR the HS narrative with 100% certainty. For
toxicities, however, the true trade-off is treatment response with
an associated risk of toxicity OR no treatment and remain with
100% certainty at baseline APC. This obtains how much chance
of response a man needs to be indifferent to the corresponding
chance of toxicity by severity. RESULTS: SG regression results
were 0.506 (p < 0.01) for baseline APC, 0.602 (p < 0.01) for
response, 0.502 (p < 0.01) for no response, and 0.318 (p < 0.01)
for disease progression. The trade-off between a chance of treat-
ment response with a corresponding chance of mild, moderate,
severe, or life-threatening toxicity yielded utility scores of 0.794
(p < 0.01), 0.715 (p < 0.01), 0.466 (p < 0.01), and 0.257 (p <
0.01), respectively. CONCLUSION: Men need at least a 21%,
28%, 55% or 74% chance of treatment response to be indiffer-
ent to treatment related toxicity depending on severity. These
measured values are more appropriate for Quality-adjusted Time
Without Symptoms of disease and Toxicity (Q-TWiST) analysis
where time without disease progression is rewarded while disease
progression with toxicities is penalized by applying a utility
weights for disease progression and time with toxicity than the
usual arbitrary ones.
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OBJECTIVES: The purpose of this study was to translate and
linguistically validate the Functional Assessment of Cancer
Therapy—Head and Neck V. 4 (FACT-H&N) for Gujarati,
Hindi, Kannada, Malayalam, Marathi, Tamil, Telugu and Urdu
translations. METHODS: The FACT-H&N was originally devel-
oped through patient and expert interviews, and validation
studies. The FACT-H&N was translated according to the stan-
dard FACIT methodology: 2 forward translations, a reconciled
version of the 2 forwards, back-translation to English, 3 inde-
pendent reviews by bilingual experts, and harmonization across
all languages. The study sample included 120 patients from 8
regions of India. Patients diagnosed with any type of head and
neck cancer completed the translated FACT-H&N and then par-
ticipated in cognitive debrieﬁng interviews. Statistical analyses
(descriptive statistics and reliability analyses) were performed on
the quantitative data, and the participant comments were ana-
lyzed qualitatively. RESULTS: Most of the languages showed
acceptable reliability ranging from 0.69 to 0.87 for the H&N
subscale despite the small sample size with the exception of
Kannada (0.13) and Tamil (0.56). There were no negative patient
comments related to the H&N speciﬁc items. However, when
item-total correlations were examined, it was found that some
items performed poorly across some languages. They included
mouth dryness, trouble breathing, and communication with
others. Of these, only the item about communication seemed to
indicate a cultural issue affecting the item’s relevance. Small
changes were made to the Telugu translation but not to the other
languages. CONCLUSION: The FACT-H&N has shown good
reliability and linguistic validity with 8 language versions. We
consider these translations to be acceptable for use in interna-
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tional research and clinical trials. These results contribute to a
better understanding of how QOL issues are perceived by head
and neck patients in India, strengthening the cross-cultural com-
parability of this instrument.
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INSURED CLAIMS DATABASES
Harris LA,Yu Y, Donato B
Bristol-Myers Squibb, Wallingford, CT, USA
OBJECTIVES: The objective of this study was to illustrate the
challenges and limitations of using claims data and developing
algorithms to study prescription patterns for metastatic breast
cancer (MBC) in patients previously treated with anthracycline
and taxane. METHODS: Extract from the PharMetrics Inte-
grated Outcomes Database between Janaury 1999 and June
2005 was used. Lacking a diagnosis code for MBC, we deﬁned
the condition = 2 ICD-9 codes for breast cancer (BC) and 1 ICD-
9 code for distant metastases. Drug exposure was deﬁned as °Y´1
NDC/J-code for anthracycline and taxane. A treatment interval
of 21 days was created to account for a high proportion of
missing or zero values for days supply of chemotherapy agents
recorded in claims database and to determine treatment duration
assigned to all agents from reference date, deﬁned as the dispense
date of the ﬁrst anthracycline or taxane prescription, whichever
occurred later. Consecutive intervals with same agents were col-
lapsed into one regimen regardless of sequence; otherwise inter-
vals were treated as separate regimens. RESULTS: Among
38,588 patients with °Y´2 BC diagnoses, 5017 (13%) exhibited
°Y´1 diagnoses for distant metastasis, 1121 (3%) were previously
exposed to an anthracycline and a taxane, and 1028 met other
criteria (age°Y´18 years and eligibility °Y´6 months). Of the 1028,
67% did not receive sequential therapy, and 80% of these had
non-chemotherapy claims 90 days following last chemotherapy,
with a mean post chemotherapy duration of 489 ± 430 days.
Among the 33% who received sequential therapy, the mean
number of sequential therapies was 2.8 ± 2.7 with mean dura-
tion of 66 ± 82 days. CONCLUSION: The current analysis illus-
trates a method of using algorithms to deﬁne MBC diagnoses
and treatment duration in claims-based treatment pattern
studies. However, such algorithms must be validated against the
patients’ medical records in order to assess the respective accu-
racy of disease and treatment pattern identiﬁcation.
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OBJECTIVES: eVOBS is an international, non-interventional,
observational study of clinical and economic outcomes in
patients who receive VELCADE for the approved indication in
multiple myeloma. METHODS: Patients who initiate VELCADE
therapy for the approved indication are eligible for the study.
Retrospective treatment data from 12 months prior to study
entry and prospective treatment data for 36 months are collected
via a secure, privacy-protected website. At study entry, submit-
ted data are electronically screened against validation rules that
have been prospectively established in consultation with multi-
ple myeloma treatment specialists and data analysis specialists.
These rules were designed to prevent missing data, duplicate data
and data outside pre-established, logical ranges. Initial inputs
require study center conﬁrmation before the system uploads data
to the central database. During the study, if there is any data that
is inconsistent with previously submitted entries, study sites
submit corrections via an audited online data change request
system. Finally, an ongoing audit process is used to validate the
quality of the data uploaded to the central database. This process
uses monthly reports to identify potential inconsistencies within
the dataset after data has been validated at entry. RESULTS:
Uploaded data undergoes quality control checks, requiring
adjustment by physicians to be minimal. Audit reports help to
redress data entry training issues, further enhancing data accu-
racy. Analysis is only conducted on patients after resolution of
outstanding supplemental data queries. CONCLUSION: The
goal of this study is document outcomes in a generalizable, rep-
resentative patient cohort. This information will broaden our
understanding of the use of VELCADE in typical clinical prac-
tice, outside of the interventional clinical trial setting. This
largely automated three-stage quality control process streamlines
the implementation of this non-interventional, observational
research and permits the inclusion of patients from a broad geo-
graphic region. The study method allows for faster analysis and
presentation of robust, pragmatic outcomes data.
CANCER—Patient-Reported Outcomes
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OBJECTIVES: To compare the impact of 11 types of cancer on
different domains of HRQL using the FACT-G and EQ-VAS.
METHODS: Patients diagnosed with advanced cancer of the
bladder, brain, breast, colorectal, head/neck, hepatobiliary/pan-
creas, kidney, lung, lymphoma, ovary or prostate completed
HRQL assessments. HRQL was compared between patient
groups for each subscale of the FACT-G, i.e., physical well-being
(PWB), social/family wellbeing (SWB), emotional well-being
(EWB) and functional well-being (FWB), and EQ-VAS, unad-
justed and adjusted for age/gender using regression models.
RESULTS: Approximately 50 patients were recruited for each
cancer group (total n = 534). Mean age (SD) ranged from 52(11)
(brain) to 70(8) (prostate). Unadjusted mean (SD) scores 
for PWB ranged from 66.8(17.2) (head/neck) to 78.1(21.3)
(prostate); for SWB ranged from 81.4(19.1) (brain) to 90.6(22.0)
(kidney); for EWB ranged from 61.7(16.0) (breast) to 72.0(16.9)
(prostate); and FWB ranged from 54.7(20.2) (head/neck) to
67.8(18.5) (prostate). EQ-5D VAS mean scores were lowest for
head/neck [61.8(21.7)] and highest for colorectal [72.0(17.1)].
Compared to lymphoma, adjusting for age/gender, PWB mean
scores (SE) were signiﬁcantly lower for patients with head/neck
[−10.9(4.0)], hepatobiliary [−10.9(4.0)], and kidney [−9.7(4.0)].
FWB mean scores were signiﬁcantly lower for head/neck 
[−10(3.2)], hepatobiliary [−8.9(3.1)], bladder [−7.7(3.6)], and
lung [−6.7(3.1)]. Patients 65 years and older had mean (SE)
scores for PWB = +9.2(2.1), EWB = +2.9(1.0), FWB = +3.1(1.6),
and EQ VAS = +4.5(2.1) compared to patients aged 45 to 64.
For median rank across all FACT subscales, hepatobiliary ranked
worst and prostate the highest. Adjusting for age and gender,
hepatobiliary ranked worst and lymphoma highest based on
FACT median scores, while breast ranked lowest and colorectal
highest based on mean VAS scores. CONCLUSION: Older
